深爱激情网
噜噜
你的位置:深爱激情网 > 噜噜 > SWAG 张凤娇(暂不招生)

SWAG 张凤娇(暂不招生)

发布日期:2024-11-09 22:35    点击次数:85

SWAG 张凤娇(暂不招生)

个情面况先容、概览SWAG

张凤娇,女,博士,无涯翻新学院后生PI,熟谙,博士生导师,荣获好意思国毒理学家阅历认证(DABT)。2004年毕业于沈阳药科大学,获中药学学士学位,2009年于同校得到药理学博士学位,毕业后赴好意思国University of Arizona药学院药理毒理询查室进行博士后询查。2014年当作引进东谈主才被聘为沈阳药科大学副熟谙,现任沈阳药科大学无涯翻新学院后生PI,特聘熟谙,博士生导师。实践室位于沈阳本部,精致围绕药理学发展的前沿领域,与特质上风学科、新兴交叉学科鸠合。主要询查标的包括:活性氧介导的分子毒理学询查、活性氧有关疾病(肿瘤、血栓、骨质疏松等)的靶点询查与新药研发以及中药有毒成份的代谢和致毒机理询查等。当作课题安逸东谈主主抓了国度当然科学基金后生基金技俩,辽宁省当然科学基金、辽宁省莳植厅一般技俩、中央财政撑抓场合高校修订发展专项资金、沈阳药科大学科研专项基金,企业互助等多个科研技俩,并参与多项国度级、省市级课题。现任好意思国毒理学会会员(full membership)、中国毒理学会会员、中国药理学会会员及辽宁省药学会药理专科委员会委员,荣获好意思国毒理学家阅历认证(DABT)。现已在外洋驰名杂志发表多篇JCR I区论文,得到专利一项,并屡次受邀在外洋学术会议上作念理论敷陈。为本科生及留学生莳植《东谈主体剖解生理学》,并为询查生莳植《高档生理》(细胞通信与信号转导部分)等。

东谈主才名称、社会兼职等

好意思国毒理学家阅历文凭(DABT)

好意思国毒理学会会员(Full Membership)

将夜视频在线观看免费

中国药理学会会员

中国毒理学会会员

辽宁省药学会药理专科委员会委员

主要询查标的

询查标的一:活性氧介导的分子毒理学询查

询查标的二:活性氧有关疾病(肿瘤、血栓、骨质疏松等)的靶点询查与新药研发

询查标的三:中药有毒成份的代谢和致毒机理询查

主抓、参与的科研技俩(含科研获奖等情况)

1.氢醌代谢产品TGHQ介导活性氧依赖性细胞圆寂形式的分子调控机制,国度当然科学基金技俩,基金编号21507093(安逸东谈主)

2.对苯二酚代谢产品TGHQ介导活性氧产生的细胞毒机制及细胞信号通路询查,辽宁省当然科学基金技俩,基金编号2015020737(安逸东谈主)

3.氢醌代谢产品TGHQ介导活性氧依赖性细胞圆寂形式的分子调控机制,辽宁省莳植厅一般技俩,基金编号,L2015529(安逸东谈主)

4.对苯二酚代谢产品TGHQ介导活性氧产生的细胞毒机制及细胞信号通路询查,沈阳药科大学科研专项基金,基金编号ZCJJ2014402(安逸东谈主)

5.广东双骏技俩,基金编号2017-协-047(安逸东谈主)

6.沈阳良耀技俩,基金编号2018-协-043(安逸东谈主)

7.沈阳良耀技俩,基金编号2018-协-044(安逸东谈主)

8.沈阳良耀技俩,基金编号2018-协-045(安逸东谈主)

9.广州仙居技俩,基金编号2018-0-4-092(安逸东谈主)

10.辽宁省当然基金带领筹画2019-ZD-0455 (安逸东谈主)

11.海南碧凯技俩,2019-0-4-064(安逸东谈主)

比年来发表代表性论文(限第一作家或通信作家,SCI须写明影响因子):

1. Wu H, Wang Y, Zhang Y, Xu F, Chen J, Duan L, Zhang T, Wang J, Zhang F (corresponding author). Breaking the Vicious Loop between Inflammation, Oxidative Stress and Coagulation, a Novel Anti-thrombus Insight of Nattokinase by Inhibiting LPS- induced Inflammation and Oxidative Stress. Redox Biol 2020 Mar 11;32 (IF=9.986).

2. Wang H, Hu B,Gao Z , Zhang F (corresponding author),Wang J. Emerging Role of Graphene Oxide as Sorbent for Pesticides Adsorption: Experimental Observations Analyzed by Molecular Modeling. Journal of Materials Science & Technology, 2020 In press (IF=6.155).

3. Wang Y, He X, Li C, Ma Y, Xue W, Wang J, Zhang T, Zhang F (corresponding author). Carvedilol Serves as a Novel CYP1B1 Inhibitor, a Systematic Drug Repurposing Approach through Structure-based Virtual Screening and Experimental Verification. Eur J Med Chem 2020 Mar 16;193 (IF=5.572).

4. Mao J, Dai W, Zhang S, Sun L, Wang H, Gao Y, Wang J, Zhang F (corresponding author). Quinone–thioether metabolites of hydroquinone play a dual role in promoting a vicious cycle of ROS generation: in vitro and in silico insights, Archives of toxicology, 2019, 93(5), 1297-1309 (IF=5.059).

5. Lin H, Hu B, He X, Mao J, Wang Y, Wang J, Zhang T, Zheng J, Peng Y, Zhang F(corresponding author). Overcoming Taxol-resistance in A549 Cells: A Comprehensive Strategy of Targeting P-gp transporter, AKT/ERK Pathways, and Cytochrome P450 Enzyme CYP1B1 by 4-hydroxyemodin, Biochemical Pharmacology, 2020, Jan;171, https://doi.org/10.1016/j.bcp.2019.113733 (IF=4.96).

6. Suleiman MR, Wang H, Huang D, Wang H, Joseph J, Huang T, Zhang F (corresponding author), Wang J, Cheng M. Discovery of small molecule inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulation and experimental validation against myeloid cell leukemia-1 (Mcl-1), J. Biomol. Struct. Dyn. 2020 Apr 20 (IF=3.31).

7. Wang Y, Joseph J, Gao Y, Hu B, Geng X, Wu D, Wang J, Zhang F (corresponding author). Revealing the interaction modes of 5-HT2A receptor antagonists and the Structure-Based virtual screening from FDA and TCMNP database, J. Biomol. Struct. Dyn. 2020 May 22 (IF=3.31).

8. Wang Y, Hu B, Feng S, Wang J, Zhang F (corresponding author). Target Recognition and Network Pharmacology for Revealing Anti-diabetes Mechanisms of Natural Product, Journal of Computational Science. 2020 In press (IF=2.642).

9. Zhang F, Munoz F, Sun L, Zhang S, Lau S, Monks T. Cell-specific regulation of Nrf2 during ROS-Dependent cell death caused by 2,3,5-tris(glutathion-S-yl)hydroquinone (TGHQ). Chem. Biol. Interact. 2019 Jan 28;302 (IF=3.723).

10. Wu H, Wang H, Zhang C, Liu Y, Xu F, Chen J, Duan L, Zhang F (corresponding author). Nattokinase-heparin exhibits beneficial efficacy and safety-an optimal strategy for CKD patients on hemodialysis. Glycoconj. J. 2019 (IF=2.197).

11. Wu H, Wang H, Xu F, Chen J, Duan L, Zhang F (corresponding author). Acute Toxicity and Genotoxicity Evaluations of Nattokinase, A Promising Agent for Cardiovascular Diseases Prevention. Regul. Toxicol. Pharmacol. 2019 Feb 8;103:205-209. doi: 10.1016/j.yrtph.2019.02.006.3 (IF=2.652).

12. Hu B, Zheng X, Wang Y, Wang J, Zhang F (corresponding author). Computational Approaches for Elucidating Protein-Protein Interactions in Cation Channel Signaling. Curr Drug Targets 2019 Sep 06 (IF=2.642).

13. Wang HB, Wang Y, Li CS, Wang HX, Geng XH, Hu BC, Wen RSWAG, Wang J, Zhang F (corresponding author). tructural basis for tailor-made selective PI3K α/β inhibitors: A computational perspective. New Journal of Chemistry. 2020 (In press) (IF=3.288)



Powered by 深爱激情网 @2013-2022 RSS地图 HTML地图

Copyright Powered by站群 © 2013-2024